Routine Medications in Otolaryngology with Not So Routine Consequences
Downloads
Article Metrics by Journal Systems
- Citations not available
- Readers 1449
- Download 414
- Altmetric Attention score:
Objective(s): We aimed to provide a directed summary of lesser-known side effects and pharmaceutical interactions of common medications used in otolaryngology practice.
Study Design: Evidence-based literature review.
Methods: We reviewed the current evidence-based literature concerning adverse effects and interactions that are of high consequence for well-known medications.
Results: This report provides a current synopsis of under-acknowledged adverse effects and interactions of intranasal corticosteroid sprays, anti-reflux medications, and antibiotics.
Conclusions: Although rare, the interactions and adverse effects presented in this article represent severe sequelae with which practicing otolaryngologists should be familiar. The information discussed in this report will aid in the identification of at-risk patients and provide otolaryngologists with proper prescribing practices in aim to promote patient safety.
Citation: Luke Stanisce, MD, Donald H. Solomon, MD, anielle McDonald, PharmD Armache, Rose Kim, MD, Yekaterina Koshkareva, MD. DOI: https://doi.org/10.52845/JORR/2023/4.4.3
Received: 28 Sep 2023; Revised: 21 Oct 2023; Accepted: 17 Nov 2023; Published Online: 30 Nov. 2023
Copyright: ©2023 Yekaterina Koshkareva, MD et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.
Funding: None
Competing interests: None
Authorship: All authors have contributed significantly to this publication.
Corresponding author: Yekaterina Koshkareva, Department of Otolaryngology – Head and Neck Surgery Cooper University Hospital Three Cooper Plaza, Suite 404 Camden NJ, 08103 E-mail: koshkareva-yekaterina@cooperhealth.edu
Article Metrics Graph
Kannry, J. Effect of E-prescribing Systems on Patient Safety. Mount Sinai Journal of Medicine. 2011;78(6):827–33.
Centers for Disease Control and Prevention (CDC). Meaningful Use. 2012. Available at http://www.cdc.gov/EHRmeaningfuluse/index.html. Accessed September 8, 2018.
Gaikwad R, Sketris I, Shepherd M, et al. Evaluation of accuracy of drug interaction alerts triggered by two electronic medical record systems in primary healthcare. Health Informatics Journal. 2007 Sep;13(3):163-177.
Miller RH, Sim I. Physicians’ Use of Electronic Medical Records: Barriers And Solutions. Health Affairs. 2004;23(2):116-126.
National Center for Health Statistics. Health, United States, 2016: With Chartbook on Long-term Trends in Health. Hyattsville, MD. 2017. Accessed September 8, 2018.
Charlesworth CJ, Smit E, Lee DSH, et al. Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989–995.
Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13(1):74.
Ortman JM, Velkoff VV, Hogan H. An Aging Nation: The Older Population in the United States, Current Population Reports, P25-1140. U.S. Census Bureau, Washington, DC. 2014.
Centers for Disease Control and Prevention. Ambulatory health care data: questionnaires, datasets, and related documentation. http://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm. Accessed September 8, 2018.
Seidman MD, Gurgel RK, Lin SY, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngology–Head and Neck Surgery. 2015 Feb;152(1):S1 - S43.
Chow AW, Benninger MS, Brook I, et al. Executive Summary: IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults, Clinical Infectious Diseases. 2012 Apr;54(8):1041–1045.
Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. British Journal of Clinical Pharmacology. 2001;51(1):103-105.
Fluticasone Nasal Spray Prescribing Information. Morton Grove, IL: Morton Grove Pharmaceuticals, Inc.; March 2016.
Lewis J, Turtle L, Khoo S, Nsutebu EN. A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops. AIDS. 2014;28(17);2636-2637.
Chen F, Kearney T, Robinson S, et al. Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect. 1999;75(4):274.
Hillebrand-Haverkort ME, Prummel MF, ten Veen JH. Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone. AIDS. 1999;13(13):1803.
Foisy MM, Yakiwchuk EM, Chiu I, et al. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: A review of the literature. HIV Med. 2008;9(6):389-396.
The University of Liverpool. HIV Drug Interactions Checker. https://www.hiv-druginteractions.org/checker. Accessed September 8 2018.
Gujral JS, Subbannan K. An Unusual Cause of Hyponatraemia. Journal of Indian Academy of Clinical Medicine. 2007;8(4):342-3.
Noctiva (Desmopressin) Prescribing Information. Milford, PA: Serenity Pharmaceuticals, LLC; March 2017.
Head K, Snidvongs K, Glew S, Scadding G, Schilder AGM, Philpott C, Hopkins C. Saline irrigation for allergic rhinitis. Cochrane Database of Systematic Reviews 2018, Issue 6. Art. No.: CD012597.
Altman KW, Stephens RM, Lyttle CS, Weiss KB. Changing impact of gastroesophageal reflux in medical and otolaryngology practice. Laryngoscope. 2005 Jul;115(7):1145-53.
Karkos, P.D., Benton, J., Leong, S.C. et al. Trends in laryngopharyngeal reflux: A British ENT survey. Eur Arch Otorhinolaryngol. 2007 May;264(5):513-7
U.S. Food and Drug Administration. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors 25 May 2010. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm213206.htm#SafetyAnnouncement. Accessed: 9 September, 2018.
U.S. Food and Drug Administration. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). 2 March 2011. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm245011. Accessed: 9 September, 2018.
U.S. Food and Drug Administration. Drug Safety Announcement: FDA Drug Safety Communication: Clostridium difficile associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). 8 February 2012. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm290510.htm. Accessed: 9 September, 2018.
Rocha A, Coelho EB, Sampaio SA, et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70(1):43-51.
Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290
Lozano R, Bibian C, Quilez R-M, et al. Clinical relevance of the (S)-citalopram–omeprazole interaction in geriatric patients. British Journal of Clinical Pharmacology. 2014;77(6):1086-1087.
Celexa (Citalopram) Prescribing Information. Irvine, CA: Allergan USA, Inc.; January 2017.
Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2016 Aug;22(2):142-152.
Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974.
Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016). BMC Cardiovasc Disord. 2017;17(1):3.
Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J Manag Care Spec Pharm. 2016;22(8):939-947.
Sherwood MW, Melloni C, Jones WS, et al. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11):e002245.
Guérin A, Mody R, Carter V, et al. Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication. PLoS ONE. 2016;11(1):e0145504.
U.S. Food and Drug Administration. FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole. March 10, 2016. Available at: http://www.fda.gov/drugs/drugsafety/ucm231161.htm. Accessed September 28, 2016.
Apriso (Mesalamine) Prescribing Information. Morrisville, NC: Salix Pharmaceuticals, Inc., 2008.
Asacol (Mesalamine) Prescribing Information. Cincinnati, OH: Procter & Gamble Pharmaceuticals, Inc., October 2007.
Lialda (Mesalamine) Prescribing Information. Wayne, PA: Shire US Inc., January 2007.
Zantac (Ranitidine) Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline, April 2009.
Bourdet DL, Pritchard JB, Thakker DR. Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine Toward Human Organic Cation Transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005;315(3):1288-97.
Chantix (Varenicline) Prescribing Information. New York, NY: Pfizer Inc., July 2011.
Champix (Varenicline) Product Monograph. Kirkland, Quebec: Pfizer Canada Inc., December 2011.
Thomas KH, Martin RM, Knipe DW, et al. Risk of Neuropsychiatric Adverse Events Associated with Varenicline: Systematic Review and Meta-Analysis. BMJ. 2015 Mar 12;350:h1109.
Feely J, Collins WC, Cullen M, et al. Potentiation of the Hypoglycaemic Response to Glipizide in Diabetic Patients by Histamine H2-Receptor Antagonists. Br J Clin Pharmacol. 1993;35:321-3.
Lee K, Mize R, Lowenstein SR. Glyburide-induced Hypoglycaemia and Ranitidine. Ann Intern Med. 1987;107:261-2.
Adebayo GI, Coker HA. Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. Eur J Clin Pharmacol. 1988;34(6):653-6.
Cate EW, Rogers JF, Powell JR. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. J Clin Pharmacol. 1986 May-Jun;26(5):372-7.
Fairbanks DF. Pocket Guide to Antimicrobial Therapy in Otolaryngology – Head and Neck Surgery. 13th Edition. The American Academy of Otolaryngology— Head and Neck Surgery Foundation. Alexandria,VA. 2007.
Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011 Oct 1;34(10):839-47.
U.S. Food and Drug Administration. Drug Safety Announcement: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. 10 July 2018. Available at https://www.fda.gov/Drugs/DrugSafety/ucm611032.htm. Accessed September 8 2018.
Roberge RJ, Kaplan R, Frank R, et al. Glyburide-Ciprofloxacin Interaction With Resistant Hypoglycemia. Ann Emerg Med. 2000;36(2):160-3.
Lin G, Hays DP, Spillane L. Refractory Hypoglycemia From Ciprofloxacin and Glyburide Interaction. J Toxicol Clin Toxicol. 2004;42(3):295-7.
Friedrich LV, Dougherty R. Fatal Hypoglycemia Associated with Levofloxacin. Pharmacotherapy. 2004;24(12):1807-12.
Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults. N Engl J Med. 2006;354(13):1352-61.
Mohr JF, McKinnon PS, Peymann PJ, et al. A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone. Pharmacotherapy. 2005;25:1303-9.
Drew BJ, Ackerman MJ, Funk M, et al. Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55(9):934-47.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. October 2005.
Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opinion on Drug Safety. 2013;12(4):497-505.
Lehmann DF, Eggleston WD, Wang D. Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug‐Induced Torsades de Pointes: A Meta‐Analysis. Pharmacotherapy. 2018;38:341-348.
Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992;36(4):830-832.
Sahai J, Healy DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35(3):302-304.
Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345.
Kuehn J, Ismael Z, Long PF, et al. Reported Rates of Diarrhea Following Oral Penicillin Therapy in Pediatric Clinical Trials. The Journal of Pediatric Pharmacology and Therapeutics: JPPT. 2015;20(2):90-104.
Boston Collaborative Drug Surveillance Program. Excess of Ampicillin Rashes Associated With Allopurinol or Hyperuricaemia. N Engl J Med. 1972;286(10):505-7.
Jick H, Porter JB. Potentiation of Ampicillin Skin Reactions by Allopurinol or Hyperuricemia. J Clin Pharmacol. 1981;21(10):456-8.
Wu H, Liu M, Wang S, et al. Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2010;32(3):597-606.
Tanizaki R, Nishijima T, Aoki T, et al. High-dose oral amoxicillin plus probenecid is highly effective for syphillis in patients with HIV infection. Clin Infect Dis. 2015;61(2):177-183.
Corvaia L, Li SC, Ioannides-Demos LL, et al. A prospective study on the effects of oral probenecid on the pharmacokinetics of intravenous ticarcillin in patients with cystic fibrosis. J Antimicrob Chemother. 1992;30(6):875-878.
Sarges P, Steinberg JM, Lewis JH. Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. Drug Saf. 2016 Sep;39(9):801-21.
Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ. 2014 Mar 11;348:g1908.
Bergeron A, Chevret S, Granata A, et al. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. JAMA. 2017;318(6):557-566.
Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol. 2008 Jan; 29(1):44-50.
Blumenthal KG, Lu N, Zhang Y, Li Y, Walensky RP, Choi HK. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ. 2018;361:k2400.
